Based on the key measurements obtained from Cullinan Oncology's financial statements, Cullinan Oncology LLC may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Cullinan Oncology's Total Stockholder Equity is very stable compared to the past year. As of the 24th of March 2025, Net Tangible Assets is likely to grow to about 646 M, though Retained Earnings are likely to grow to (349.8 M). Key indicators impacting Cullinan Oncology's financial strength include:
Investors should never underestimate Cullinan Oncology's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Cullinan Oncology's cash flow, debt, and profitability to make informed and accurate decisions about investing in Cullinan Oncology LLC.
Net Income
(159.01 Million)
Cullinan
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Net Income Per Share
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Ev To Operating Cash Flow
Pe Ratio
Ev To Free Cash Flow
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Enterprise Value Over E B I T D A
Roic
Payables Turnover
Roe
Return On Tangible Assets
Earnings Yield
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Free Cash Flow Operating Cash Flow Ratio
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Price Fair Value
Return On Capital Employed
Return On Assets
Return On Equity
Other Cashflows From Financing Activities
Capital Expenditures
Total Cash From Financing Activities
Change To Liabilities
Sale Purchase Of Stock
Change In Cash
Net Borrowings
Total Cash From Operating Activities
Change To Account Receivables
Change To Operating Activities
Net Income
Change To Netincome
End Period Cash Flow
Investments
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Depreciation
Other Non Cash Items
Issuance Of Capital Stock
Other Cashflows From Investing Activities
Stock Based Compensation
Total Assets
Total Current Liabilities
Other Liab
Accounts Payable
Other Current Assets
Total Liab
Common Stock
Total Stockholder Equity
Net Tangible Assets
Retained Earnings
Cash
Other Assets
Long Term Debt
Net Receivables
Short Long Term Debt
Total Current Assets
Short Term Debt
Other Current Liab
Property Plant And Equipment Net
Net Debt
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Stockholder Equity
Net Invested Capital
Property Plant And Equipment Gross
Accumulated Other Comprehensive Income
Capital Stock
Net Working Capital
Property Plant Equipment
Long Term Investments
Capital Lease Obligations
Interest Expense
Selling General Administrative
Gross Profit
Operating Income
Net Income From Continuing Ops
Ebit
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Research Development
Non Recurring
Net Interest Income
Interest Income
Depreciation And Amortization
Other Operating Expenses
Ebitda
Reconciled Depreciation
Minority Interest
Tax Provision
Probability Of Bankruptcy
Understanding current and past Cullinan Oncology Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Cullinan Oncology's financial statements are interrelated, with each one affecting the others. For example, an increase in Cullinan Oncology's assets may result in an increase in income on the income statement.
Cullinan Oncology competes with Bolt Biotherapeutics, Day One, Lyra Therapeutics, Autolus Therapeutics, and Sana Biotechnology. Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Cullinan Management operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 31 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Cullinan Oncology's current stock value. Our valuation model uses many indicators to compare Cullinan Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cullinan Oncology competition to find correlations between indicators driving Cullinan Oncology's intrinsic value. More Info.
Cullinan Oncology LLC is rated fourth in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Cullinan Oncology's Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Cullinan Oncology by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Cullinan Oncology LLC Systematic Risk
Cullinan Oncology's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Cullinan Oncology volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Cullinan Oncology LLC correlated with the market. If Beta is less than 0 Cullinan Oncology generally moves in the opposite direction as compared to the market. If Cullinan Oncology Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Cullinan Oncology LLC is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Cullinan Oncology is generally in the same direction as the market. If Beta > 1 Cullinan Oncology moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Cullinan Oncology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cullinan Oncology's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Cullinan Oncology growth as a starting point in their analysis.
Cullinan Oncology March 24, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Cullinan Oncology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cullinan Oncology LLC. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cullinan Oncology LLC based on widely used predictive technical indicators. In general, we focus on analyzing Cullinan Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cullinan Oncology's daily price indicators and compare them against related drivers.
When determining whether Cullinan Oncology LLC is a strong investment it is important to analyze Cullinan Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cullinan Oncology's future performance. For an informed investment choice regarding Cullinan Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.78)
Return On Assets
(0.22)
Return On Equity
(0.32)
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.